RARRES1 inhibits hepatocellular carcinoma progression and increases its sensitivity to lenvatinib through interaction with SPINK2
Abstract Background Lenvatinib is an oral small molecule inhibitor approved for treating patients with unresectable hepatocellular carcinoma (HCC) worldwide. Increasing cell sensitivity to lenvatinib would be an effective method of improving therapeutic efficacy. Methods High throughput methods was...
Salvato in:
| Autori principali: | , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMC
2024-02-01
|
| Serie: | Biology Direct |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1186/s13062-024-00459-0 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|